Cargando…
A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy
Background Unfractionated heparin is used to prevent coagulation activation in patients undergoing extracorporeal membrane oxygenation (ECMO) support. We designed this study to determine the preferable indicator for anticoagulation monitoring. Methods We conducted a retrospective study and divided...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281775/ https://www.ncbi.nlm.nih.gov/pubmed/35882351 http://dx.doi.org/10.1055/a-1796-8652 |
_version_ | 1785061060027351040 |
---|---|
author | Liu, Ying Yuan, Zhiyong Han, Xiaoning Song, Kai Xing, Jinyan |
author_facet | Liu, Ying Yuan, Zhiyong Han, Xiaoning Song, Kai Xing, Jinyan |
author_sort | Liu, Ying |
collection | PubMed |
description | Background Unfractionated heparin is used to prevent coagulation activation in patients undergoing extracorporeal membrane oxygenation (ECMO) support. We designed this study to determine the preferable indicator for anticoagulation monitoring. Methods We conducted a retrospective study and divided the patients into an activated coagulation time (ACT)-target group and an activated partial thromboplastin time (aPTT)-target group. The correlations between ACT, aPTT, and the heparin dose were explored. Results Thirty-six patients were included (19 aPTT-target and 17 ACT-target patients); a total of 555 matched pairs of ACT/aPTT results were obtained. The correlation between the ACT and aPTT measurements was Spearman's Rank Correlation Coefficient ( rs ) = 0.518 in all 555 pairs. The Bland–Altman plot showed data points outside the displayed range (51.2–127.7), suggesting that the agreement between ACT and aPTT was poor. The aPTT group had fewer heparin dose changes (2.12 ± 0.68 vs. 2.57 ± 0.64, p = 0.05) and a lower cumulative heparin dose (317.6 ± 108.5 vs. 396.3 ± 144.3, p = 0.00) per day than the ACT group. There was no difference in serious bleeding (9 vs . 5; p = 0.171) or embolism events (3 vs. 3; p = 1.0) or in the red blood cell and fresh frozen plasma transfusion volumes between the ACT- and aPTT-target groups. Similarly, there was no significant difference in the ECMO duration (9 [4–15] days vs . 4 [3–14] days; p = 0.124) or length of ICU hospitalization (17 [5–32] days vs . 13 [4–21] days; p = 0.451) between the groups. Conclusion The correlation between ACT and aPTT and the heparin dose was poor. The aPTT group had fewer daily heparin dose changes and a lower cumulative heparin dose per day than the ACT group, with no more bleeding and thrombotic events. Therefore, we recommend aPTT rather than ACT to adjust heparin dose in the absence of better monitoring indicators. |
format | Online Article Text |
id | pubmed-10281775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-102817752023-06-21 A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy Liu, Ying Yuan, Zhiyong Han, Xiaoning Song, Kai Xing, Jinyan Hamostaseologie Background Unfractionated heparin is used to prevent coagulation activation in patients undergoing extracorporeal membrane oxygenation (ECMO) support. We designed this study to determine the preferable indicator for anticoagulation monitoring. Methods We conducted a retrospective study and divided the patients into an activated coagulation time (ACT)-target group and an activated partial thromboplastin time (aPTT)-target group. The correlations between ACT, aPTT, and the heparin dose were explored. Results Thirty-six patients were included (19 aPTT-target and 17 ACT-target patients); a total of 555 matched pairs of ACT/aPTT results were obtained. The correlation between the ACT and aPTT measurements was Spearman's Rank Correlation Coefficient ( rs ) = 0.518 in all 555 pairs. The Bland–Altman plot showed data points outside the displayed range (51.2–127.7), suggesting that the agreement between ACT and aPTT was poor. The aPTT group had fewer heparin dose changes (2.12 ± 0.68 vs. 2.57 ± 0.64, p = 0.05) and a lower cumulative heparin dose (317.6 ± 108.5 vs. 396.3 ± 144.3, p = 0.00) per day than the ACT group. There was no difference in serious bleeding (9 vs . 5; p = 0.171) or embolism events (3 vs. 3; p = 1.0) or in the red blood cell and fresh frozen plasma transfusion volumes between the ACT- and aPTT-target groups. Similarly, there was no significant difference in the ECMO duration (9 [4–15] days vs . 4 [3–14] days; p = 0.124) or length of ICU hospitalization (17 [5–32] days vs . 13 [4–21] days; p = 0.451) between the groups. Conclusion The correlation between ACT and aPTT and the heparin dose was poor. The aPTT group had fewer daily heparin dose changes and a lower cumulative heparin dose per day than the ACT group, with no more bleeding and thrombotic events. Therefore, we recommend aPTT rather than ACT to adjust heparin dose in the absence of better monitoring indicators. Georg Thieme Verlag KG 2022-07-26 /pmc/articles/PMC10281775/ /pubmed/35882351 http://dx.doi.org/10.1055/a-1796-8652 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Liu, Ying Yuan, Zhiyong Han, Xiaoning Song, Kai Xing, Jinyan A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy |
title | A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy |
title_full | A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy |
title_fullStr | A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy |
title_full_unstemmed | A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy |
title_short | A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy |
title_sort | comparison of activated partial thromboplastin time and activated coagulation time for anticoagulation monitoring during extracorporeal membrane oxygenation therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281775/ https://www.ncbi.nlm.nih.gov/pubmed/35882351 http://dx.doi.org/10.1055/a-1796-8652 |
work_keys_str_mv | AT liuying acomparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy AT yuanzhiyong acomparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy AT hanxiaoning acomparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy AT songkai acomparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy AT xingjinyan acomparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy AT liuying comparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy AT yuanzhiyong comparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy AT hanxiaoning comparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy AT songkai comparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy AT xingjinyan comparisonofactivatedpartialthromboplastintimeandactivatedcoagulationtimeforanticoagulationmonitoringduringextracorporealmembraneoxygenationtherapy |